A private business has helped supercharge a controversial federal drug program. Patients and insurers have been left with big bills. Drugs (Pharmaceuticals), Hospitals, Nonprofit Organizations, Poverty, Prices (Fares, Fees and Rates), Government Contracts and Procurement, Health Insurance and Managed Care, Regulation and Deregulation of Industry, 340B Drug Pricing Program, Apexus LLC, Vizient Inc, Health and Human Services Department, Health Resources and Services Administration, United States NYT > Health
A private business has helped supercharge a controversial federal drug program. Patients and insurers have been left with big bills.
